Summary: In H2 2026, the US stock market offers ample layout opportunities in AI, biotech, and clean energy sectors. From a macro perspective, this article analyzes the core logic of three high-growth sectors, selects quality stocks and ETFs, and helps investors seize US stock investment opportunities in the second half.
As of mid-2026, the US stock market shows structural divergence driven by the AI revolution, biotech breakthroughs, and energy transition. How can investors select quality targets and build a balanced portfolio in the second half? This article, based on the latest industry dynamics and institutional views, uncovers core opportunities in three high-growth sectors.
1. Artificial Intelligence: From Infrastructure to Application Deployment
In 2026, AI computing power demand remains strong, but market focus is shifting from hardware to software and applications. According to Gartner, the global AI software market will exceed $200 billion in 2026, with a compound annual growth rate of over 30%.
Core Picks
- NVIDIA (NVDA): As the AI chip leader, its Blackwell architecture GPU penetration in data centers continues to increase. Q2 2026 earnings show data center revenue up 120% year-over-year, far exceeding expectations.
- Microsoft (MSFT): Azure AI services revenue growth reached 55%, Copilot commercial version users exceeded 100 million, with deep AI cloud ecosystem moats.
- ETF Selection: Global X Robotics & AI ETF (BOTZ): Holdings cover leading companies across the AI industry chain. Since the beginning of 2026, its return has been 28%, with lower volatility than individual stocks.
2. Biotechnology: AI + Gene Therapy Usher in a New Era
2026 is a turning point for biotech. The FDA approved the first AI-assisted designed antibody drug, and gene editing therapies achieved breakthrough progress in sickle cell disease and hemophilia. According to Evaluate Pharma data, the overall R&D return rate of the biotech sector rebounded to 12% in 2026, the highest in five years.
Core Picks
- Vertex Pharmaceuticals (VRTX): Global rare disease leader. Its gene editing therapy CTX001 is expected to launch globally in 2027, with analyst target price showing 20% upside from current price.
- Intellia Therapeutics (NTLA): Pioneer in in-vivo gene editing. A set of liver disease data announced in Q2 2026 was exciting, with stock price up 35% within a month.
- ETF Selection: ARK Genomic Revolution ETF (ARKG): Focuses on gene therapy and precision medicine, heavily holds frontier companies like NTLA, CRSP. Cumulative gain in 2026 is 22%.
3. Clean Energy: Policy and Cost Dual Drivers
Despite global energy price volatility in 2026, clean energy investment grew against the trend. The International Energy Agency (IEA) expects global renewable energy investment to exceed fossil fuel investment for the first time in 2026, with tax credits from the U.S. Inflation Reduction Act continuing to deliver dividends.
Core Picks
- NextEra Energy (NEE): Largest wind and solar operator in the U.S. Added 4.2 GW capacity in Q2 2026, up 18% YoY. Dividend increased for 25 consecutive years.
- Enphase Energy (ENPH): Leading microinverter supplier. Benefiting from the expansion of the U.S. residential solar market, net profit in Q2 2026 increased 40% YoY.
- ETF Selection: iShares Global Clean Energy ETF (ICLN): Covers the entire global clean energy chain. Valuation in 2026 is at a historical low, with institutional holdings rising to 65%.
Investment Strategy and Risk Warning
In H2 2026, the US stock market still faces uncertainties such as Fed interest rate policy and geopolitics. It is recommended that investors adopt a 'core + satellite' strategy: allocate 50% of positions to AI and clean energy blue-chip stocks and ETFs (e.g., BOTZ, ICLN), 30% to high-beta biotech targets (e.g., VRTX, ARKG), and keep the remaining 20% in cash or short-term bond ETFs to cope with short-term volatility.
In terms of risks, tightened AI regulation, failure of gene therapy clinical trials, and rollback of clean energy subsidies may trigger sector pullbacks. Investors should reduce timing risk through dollar-cost averaging or phased position building, and pay attention to performance verification in the Q3 2026 earnings season.
